Hepatic and hematological adverse effects of long-term low-dose methotrexate therapy in rheumatoid arthritis: An observational study | Zendy

Lily Dubey | Zendy; Suparna Chatterjee | Zendy; Alakendu Ghosh | Zendy

Open Access

Hepatic and hematological adverse effects of long-term low-dose methotrexate therapy in rheumatoid arthritis: An observational study

Author(s) -

Lily Dubey,

Suparna Chatterjee,

Alakendu Ghosh

Publication year - 2016

Publication title -

indian journal of pharmacology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.286

H-Index - 59

eISSN - 1998-3751

pISSN - 0253-7613

DOI - 10.4103/0253-7613.190761

Subject(s) - medicine , adverse effect , leukopenia , rheumatoid arthritis , methotrexate , gastroenterology , alanine transaminase , concomitant , anemia , chemotherapy

Methotrexate (MTX) is the most commonly used cost-effective disease-modifying antirheumatoid drug (DMARD). Its main dose-limiting adverse effects are hepatic and hematopoietic. This cross-sectional, observational study evaluated the prevalence of hepatic and hematological adverse effects with long-term low-dose MTX therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research